Collaboration combines BlueRock’s leading induced pluripotent stem cell (iPSC) platform technology and genome biology expertise with Senti Bio’s proprietary gene circuit technology platform, including Smart Sensors and Regulator Dials CAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif., May 26, 2021 (GLOBE NEWSWIRE) — BlueRock Therapeutics […]
Gornalusse et al demonstrate that master cell banks of pluripotent stem cells can be gene edited to ablate HLA receptors and avoid T cell recognition. In addition, these banks are engineered to express a recombinant receptor to prevent innate cell clearance. This escape from […]
Moyes et al. validate approaches to engineer adult macrophages for payload delivery, establishing a platform with widespread utility. This is an effective proof point for functional derivation of similar macrophages derived from pluripotent stem cell sources. Read more.
Brunstein et al describe successful use of cord blood derived regulatory T cells in prevention of graft vs host disease (GvHD). This establishes a clinical response to target in deriving similar cells from pluripotent stem cells. Read more.
Dr. Bruce Blazar brings a wealth of knowledge as a leader in transplantation and immunobiology Dr. Courtney Crane brings key expertise in myeloid cell biology and genetic engineering CAMBRIDGE, Mass., Jan. 16, 2019 – BlueRock Therapeutics, LP, an engineered cell therapy company leveraging its novel […]
